 |
 |

Persistence of Reduction in Blood Pressure and Mortality of Participants in the Hypertension Detection and Follow-up Program
Hypertension Detection and Follow-up Program Cooperative Group;
Neil Shulman, MD;
Elbert Tuttle, Jr, MD;
George Entwisle, MD;
Aristide Apostolides, DVM, PhD;
Albert Oberman, MD;
Harold W. Schnaper, MD;
Edward H. Kass, MD, PhD;
James O. Taylor, MD;
B. Frank Polk, MD;
Jeremiah Stamler, MD;
Rose Stamler, MA;
Flora Gosch, MD;
Nemat O. Borhani, MD;
Beth Newman, PhD;
Linda Harlan, PhD;
Marshall Lee, MD;
John W. Jones, MD;
Sandra A. Daugherty, MD, PhD;
H. A. Tyroler, MD;
Curtis G. Hames, MD;
Siegfried Heyden, MD;
Lawrence M. Slotkoff, MD, PhD;
Socrates Fotiu, MD;
Herbert G. Langford, MD;
John Abernathy, MD;
Myra Tyler, MD;
Morton H. Maxwell, MD;
Andrew J. Lewin, MD;
Roger Detels, MD;
Reuben Berman, MD;
Ronald J. Prineas, MB, BS, PhD;
Richard S. Crow, MD;
M. Donald Blaufox, MD, PhD;
Sylvia Wassertheil-Smoller, PhD;
C. Hilmon Castle, MD;
Josephine Kasteller, PhD;
C. Morton Hawkins, ScD;
Charles E. Ford, PhD;
Barry R. Davis, MD, PhD;
Agostino Molteni, MD, PhD;
Kenneth A. Schneider, MD;
Edward J. Fitzsimmons, PhD;
Ronald J. Prineas, MB, BS,;
PhD;
Gerald H. Payne, MD, MPH;
Thomas P. Blaszkowski, PhD;
William J. Zukel, MD;
Alvin P. Shapiro, MD;
Glenn E. Bartsch, PhD;
Kenneth G. Berge, MD;
Edward S. Cooper, MD;
Edward D. Frohlich, MD;
Richard H. Gadsden, PhD;
David L. Sackett, MD;
Joseph A. Wilber, MD;
William J. Zukel, MD;
W. McFate Smith, MD, MPH;
Walter M. Kirkendall, MD;
Curtis L. Meinert, PhD;
Louis S. Monk, PhD;
Richard D. Remington, PhD;
Alvin P. Shapiro, MD;
Herbert G. Langford, MD;
Jeremiah Stamler, MD;
Edward H. Kass, MD, PhD;
Harold W. Schnaper, MD;
Thomas P. Blaszkowski, PhD;
Max Halperin, PhD;
William J. Zukel, MD
JAMA. 1988;259(14):2113-2122.
Abstract
 |  |
The Hypertension Detection and Follow-up Program (HDFP) previously described a significant reduction in five-year, all-cause mortality in its intensively treated stepped care (SC) group relative to its referred care (RC) control group. At the time this finding was described, a proportion of the SC cohort had been treated for periods as long as 6.7 years, but comparable RC and SC mortality data beyond five years were not available. These data, which are described herein, indicate that the 6.7-year life-table mortality rates were 95.1/1000 participants for SC vs 116.3/1000 participants for RC, a larger mortality difference than was observed at five years. This favorable finding for SC extended to all major subgroups, including white women and those aged 30 to 49 years at trial entry. Six months after the close of the treatment trial, a two-year posttrial surveillance study, which extended mortality follow-up to 8.3 years, was conducted. The posttrial use of antihypertensive medication declined in SC and increased in RC participants so that by the end of the posttrial period, there was little difference in the percentages of SC and RC participants taking medication. Control of blood pressure, indicated by mean diastolic blood pressure and by percent of participants with a pressure of 90 mm Hg or less, was slightly better for SC than for RC participants (SC group, 86.5 mm Hg and 68% controlled; RC group, 87.8 mm Hg and 62% controlled). The absolute mortality advantage found at 6.7 years persisted and increased throughout the posttrial period of follow-up despite discontinuation of the formal SC therapy program. It is postulated that regression of hypertensive end-organ changes brought about by the more effective SC treatment caused this favorable outcome.
(JAMA 1988;259:2113-2122)
Author Affiliations
 |  |
Atlanta: Emory University; Baltimore: University of Maryland; Birmingham: University of Alabama; Boston: Brigham and Women's Hospital and Harvard University Medical School; Chicago: Northwestern University; Davis: University of California; East Lansing: Michigan State University; Evans County, Georgia: Evans County Health Department; Washington, DC: Georgetown University; Jackson: University of Mississippi Medical School; Los Angeles: Cedars-Sinai and UCLA Medical Centers; Minneapolis: Mount Sinai Hospital and University of Minnesota; New York: Albert Einstein College of Medicine; Salt Lake City: University of Utah; Coordinating Center, Houston: The University of Texas School of Public Health; Central Laboratory, Chicago: Northwestern Memorial Hospital; ECG Center, Minneapolis: University of Minnesota; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md; (Chairman), University of Pittsburgh School of Medicine; School of Public Health, University of Minnesota, Minneapolis; Mayo Clinic, Rochester, Minn; Hospital of theUniversity of Pennsylvania, Philadelphia; Alton Ochsner Medical Foundation, New Orleans; Medical University of South Carolina, Charleston; McMaster University Medical Center, Hamilton, Ontario; Georgia Department of Human Resources, Atlanta; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.; (Chairman), University of California-USPHS Hospital, San Francisco; The University of Texas Health Science Center and School of Medicine, Houston; School of Hygiene and Public Health, The Johns Hopkins University, Baltimore; Silver Spring, Md; University of lowa, Iowa City; University of Pittsburgh School of Medicine; University of Mississippi Medical Center, Jackson; Northwestern University Medical School, Chicago; Brigham and Women's Hospital and Harvard University Medical School, Boston; University of Alabama at Birmingham; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md; George Washington University, Bethesda, Md; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.
From the Hypertension Detection and Follow-up Program, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.4
Footnotes
Members of the ad hoc committee that prepared this manuscript on behalf of the HDFP Cooperative Group were as follows: Sandra A. Daugherty, MD, PhD (University of Nevada, Reno); Charles E. Ford, PhD (The University of Texas School of Public Health, Houston); J. David Curb, MD (National Institute on Aging, Bethesda, Md); Herbert Langford, MD (University of Mississippi Medical Center, Jackson); James O. Taylor, MD (Harvard Medical School, Boston); Gerald H. Payne, MD (National Heart, Lung, and Blood Institute, Bethesda, Md); Nemat O. Borhani, MD (University of California at Davis); Sara Pressel, MS, and C. Morton Hawkins, ScD (The University of Texas School of Public Health, Houston).
Reprint requests to Coordinating Center for Clinical Trials, The University of Texas School of Public Health, 1200 Herman Pressler St, Suite 801, Houston, TX 77030 (Charles E. Ford, PhD).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
So, What's New?
Kuller
Stroke 2007;38:1427-1429.
FULL TEXT
Diuretics Are Color Blind
Neaton and Kuller
JAMA 2005;293:1663-1666.
FULL TEXT
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian et al.
Hypertension 2003;42:1206-1252.
ABSTRACT
| FULL TEXT
Cost as a Barrier to Medical Care in Relation to Unemployment Rates
Nelson et al.
NEJM 1998;339:1644-1645.
FULL TEXT
Behavior and Biology: The Basic Sciences for AHA Action : Presented at the 70th Scientific Sessions of the American Heart Association November 9, 1997 Orlando, Florida
Hill
Circulation 1998;97:807-810.
FULL TEXT
Behavior and Biology: The Basic Sciences for AHA Action : Presented at the 70th Scientific Sessions of the American Heart Association November 9, 1997 Orlando, Florida
Hill
Stroke 1998;29:739-742.
FULL TEXT
Different Concepts in First-Line Treatment of Essential Hypertension: Comparison of a Low-Dose Reserpine-Thiazide Combination With Nitrendipine Monotherapy
Kronig et al.
Hypertension 1997;29:651-658.
ABSTRACT
| FULL TEXT
Diabetes mellitus and raised serum triglyceride concentration in treated hypertension--are they of prognostic importance? Observational study
Samuelsson et al.
BMJ 1996;313:660-663.
ABSTRACT
| FULL TEXT
Efficacy and Tolerance of Antihypertensive Treatment in Men and Women With Stage 1 Diastolic Hypertension: Results of the Treatment of Mild Hypertension Study
Lewis et al.
Arch Intern Med 1996;156:377-385.
ABSTRACT
The number needed to treat: a clinically useful nomogram in its proper context
Chatellier et al.
BMJ 1996;312:426-429.
FULL TEXT
Does Antihypertensive Treatment of the Elderly Prevent Cardiovascular Events or Prolong Life? A Meta-analysis of Hypertension Treatment Trials
Pearce et al.
Arch Fam Med 1995;4:943-949.
ABSTRACT
Thiazides and Hypertension in the Elderly
Gifford and Kaplan
Hypertension 1995;25:1052-1052.
FULL TEXT
Antihypertensive Therapy in Dyslipidemic Men : Effects on Coronary Heart Disease Incidence and Total Mortality
Manttari et al.
Hypertension 1995;25:47-52.
ABSTRACT
| FULL TEXT
Recent Evidence on Drug Therapy of Mild to Moderate Hypertension and Decreased Risk of Coronary Heart Disease
Hebert et al.
Arch Intern Med 1993;153:578-581.
ABSTRACT
An Overview of the Meta-analyses of the Hypertension Treatment Trials
Moser et al.
Arch Intern Med 1991;151:1277-1279.
ABSTRACT
National Education Programs Working Group Report on the Management of Patients with Hypertension and High Blood Cholesterol
Working Group on Management of Patients with Hyper
ANN INTERN MED 1991;114:224-237.
ABSTRACT
Who Really Determines Your Patients' Prescriptions?
Moser et al.
JAMA 1991;265:498-500.
ABSTRACT
Mortality Rates After 10.5 Years for Participants in the Multiple Risk Factor Intervention Trial: Findings Related to A Priori Hypotheses of the Trial
The Multiple Risk Factor Intervention Trial Resear
JAMA 1990;263:1795-1801.
ABSTRACT
Diuretics--Current Issues and Updates
Carasiti
Journal of Pharmacy Practice 1990;3:295-304.
|